tive amount of the γ-crystalline form of ivabradine hydrochloride of claim **1**.

5. A solid pharmaceutical composition comprising as active ingredient the γ-crystalline form of ivabradine hydrochloride of claim **2**, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers.

6. A method for treating a condition selected from angina pectoris, myocardial infarct, and heart failure, such method comprising administering to a human, a therapeutically effective amount of the γ-crystalline form of ivabradine hydrochloride of claim **2**.

* * * * *